Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Valneva
Biotech
Valneva sells priority review voucher for $103M, R&D to benefit
Vaccine maker Valneva is giving its R&D unit a $103 million gift courtesy of selling an FDA priority review voucher for tropical disease.
James Waldron
Feb 5, 2024 9:15am
Pfizer, Valneva overcome CRO Lyme disease recruitment problems
Dec 5, 2023 3:20pm
Pfizer links Lyme booster to phase 2 pediatric antibody response
Sep 7, 2023 7:30am
Pfizer cuts enrollment for Lyme disease trial after CRO debacle
Aug 22, 2023 1:00pm
FDA delays decision on Valneva's chikungunya vaccine by 3 months
Aug 14, 2023 6:00am
Bavarian Nordic goes 2 for 2 in key chikungunya vaccine trials
Aug 7, 2023 5:40am